Paper Contents
Abstract
Abstract The present study aims to develop and evaluate a novel gastroretentive floating tablet formulation of Pirenzepine Dihydrochloride employing a chitosan-graphene oxide nanocomposite as a novel matrix-forming and buoyancy-enhancing excipient. Pirenzepine, an antimuscarinic agent used for peptic ulcer treatment, suffers from limited gastric residence time affecting its bioavailability. To overcome this, the formulation incorporated chitosan-graphene oxide nanocomposite, which synergistically combines the mucoadhesive and swelling properties of chitosan with the exceptional mechanical strength and surface area of graphene oxide nanosheets, thereby improving floating behavior and sustaining drug release. Tablets were prepared by direct compression, using sodium bicarbonate as a gas-generating agent to facilitate buoyancy and HPMC K100M to modulate drug release. The optimized formulation exhibited rapid floating lag time (<30 seconds), sustained buoyancy (>12 hours), and a controlled release profile over 24 hours. Physicochemical characterization confirmed uniformity, mechanical strength, and compatibility of components. In vitro dissolution studies demonstrated a significant improvement in sustained release compared to conventional formulations. This novel floating drug delivery system offers promising potential for enhancing the therapeutic efficacy and patient compliance of Pirenzepine by prolonging gastric residence time and providing controlled release.Keywords Pirenzepine Dihydrochloride , Floating tablet , Gastroretentive drug delivery , Chitosan-graphene oxide nanocomposite , Controlled release Formulation .
Copyright
Copyright © 2025 Lawande Nikita Pramod . This is an open access article distributed under the Creative Commons Attribution License.
